Products & Services · Product revenues, net
ALYFTREK — Product revenues, net
Vertex Pharmaceuticals ALYFTREK — Product revenues, net increased by 53.9% to $380.10M in Q4 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market penetration and patient adoption, while a decrease may signal competitive pressure, patent expiration, or market saturation.
Detailed definition
This metric represents the total net sales generated from the specific pharmaceutical product or therapeutic line after...
Peer comparison
Comparable to net product sales reported by other biotechnology and pharmaceutical companies for specific branded therapies or drug franchises.
Metric ID:
vrtx_segment_alyftrek_product_revenues_netHistorical Data
12 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $53.90M | $156.80M | $247.00M | $380.10M |
| QoQ Change | — | — | — | — | — | — | — | — | — | +190.9% | +57.5% | +53.9% |
Range$0.00 – $380.10M
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's alyftrek — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported alyftrek — product revenues, net of $380.10M in Q4 2025.
- What does alyftrek — product revenues, net mean?
- The total net sales revenue generated by a specific pharmaceutical product or therapeutic line.